



The registry status and perceived efficacy of drugs used AUD in Europe


The 2015 EUFAS survey
Jørgen G. Bramness
Friedrich Würst




Acamprosate




Disulfiram




Nalmefene




Naltrexone




Are drugs for AUD reimbursed?



Perceived efficacy



Guidelines?



Relationship between variables

	Acamprosate	Disulfiram	Nalmefene	Naltrexone
Guidelines vs. perceived efficacy	0,28	0,18	-0,19	-0,19
Guidelines vs. reimbursement	0,30	0,18	0,09	0,09
Perceived efficacy vs. reimbursement	0,25	0,45	-0,29	-0,29